Milestone Pharmaceuticals (MIST) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, to be held virtually.
Proxy materials are available online, with options for electronic or paper delivery.
Shareholders are encouraged to review materials and vote electronically or by phone.
Voting matters and shareholder proposals
Election of eight directors is up for shareholder vote.
Appointment of PricewaterhouseCoopers LLP as external auditors is proposed.
Amendment to the 2019 Equity Incentive Plan to increase authorized shares by 6.8 million is proposed.
Advisory approval of executive compensation is included as a say-on-pay proposal.
Board of directors and corporate governance
Board recommends voting in favor of all four proposals.
List of director nominees includes Stuart M. Duty, Seth H.Z. Fischer, Lisa M. Giles, Joseph Oliveto, Joseph C. Papa, Andrew R. Saik, Michael Tomsicek, and Robert J. Wills, PhD.
Latest events from Milestone Pharmaceuticals
- FDA review targets March 2025, with a mid-year launch and broad access planned.MIST
Investor update14 May 2026 - Etripamil offers rapid, self-administered PSVT relief, meeting key unmet needs for many patients.MIST
Study update14 May 2026 - Shelf registration enables up to $300M in offerings, including $100M at-the-market with Cantor Fitzgerald.MIST
Registration filing13 May 2026 - Strong CARDAMYST launch, 600 prescriptions, $0.2M revenue, and expanding coverage in Q1 2026.MIST
Q1 202613 May 2026 - Annual meeting to vote on directors, auditor, equity plan, and executive pay, with strong governance.MIST
Proxy filing1 May 2026 - CARDAMYST launches as the first new PSVT therapy in decades, targeting rapid market adoption.MIST
Corporate presentation29 Apr 2026 - FDA decision on CARDAMYST pending; net loss narrows as launch and new trials approach.MIST
Q4 202423 Apr 2026 - CARDAMYST launches with strong clinical data, broad provider targeting, and robust financial runway.MIST
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - CARDAMYST launched with strong early demand and $200M in cash, supporting growth into 2027.MIST
Q4 202520 Mar 2026